Pacer Advisors’s Cullinan Oncology CGEM Stock Holding History

Pacer Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-595	Closed	-$10.4K	–	2587
2024 Q2	$10.4K	Buy	595 +145	+32%	+$3.09K	﹤0.01%	3544
2024 Q1	$7.67K	Buy	+450	New	+$6.95K	﹤0.01%	3568

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pacer Advisors's CGEM Position: Q3 2024 in Review

Pacer Advisors sold out of Cullinan Oncology (CGEM) in Q3 2024, closing a stake of 595 shares — an estimated $10.4K sold.

Pacer Advisors first reported a position in CGEM in Q1 2024 and held it in 2 quarters. The position peaked at $10.4K in Q2 2024. 137 funds tracked by Wall St. Rank hold CGEM as of Q3 2024.

Pacer Advisors reported no remaining Cullinan Oncology position as of Q3 2024 after selling out during the quarter.
Pacer Advisors sold 595 Cullinan Oncology shares in Q3 2024, an estimated $10.4K.
Pacer Advisors first reported a position in Cullinan Oncology in Q1 2024 and held it in 2 quarters.
Pacer Advisors's Cullinan Oncology position peaked at $10.4K in Q2 2024.
137 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.